PTN.DU Stock Analysis
PT
Uncovered
Palatin Technologies Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 33 full-time employees. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need. Its MCr system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. The Company’s commercial product Vyleesi (bremelanotide injection), is used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Company’s pipeline development programs include PL9643 MCr Agonist for dry eye disease and anti-inflammatory ocular indications, Oral PL8177 for inflammatory bowel diseases, and Melanocortin peptides for diabetic retinopathy. Its product development activities in inflammation disease indications focus on development of MCr peptides for ocular conditions, as well as conditions in the gut and kidney.